Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

No annotations are provided, so the description carries the full burden of behavioral disclosure. It does not explicitly state whether the tool is read-only, what output format to expect, or any limitations. The description is descriptive rather than behavioral, leaving the agent without clear expectations for invocation results.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is concise, using two sentences to convey the tool's scope. It is front-loaded with the primary topic and includes relevant details (EU CTR, phases, CTIS, German specifics) without unnecessary fluff. Every word adds value.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Given the tool's simple scope (one optional parameter, no output schema, no annotations), the description provides adequate context for what the tool covers. However, it could be slightly more complete by mentioning the return format or whether the tool is informational only, but this is not a major gap.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

The input schema provides a description for the 'phase' parameter listing possible values (PRECLINICAL, PHASE_I, etc.), achieving 100% schema description coverage. The tool description adds no extra semantic information about the parameter itself, so it remains at the baseline of 3.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Does the description clearly state what the tool does and how it differs from similar tools?

The description clearly identifies the tool as covering clinical trial phase requirements under EU CTR 536/2014, including Phase I-IV details, CTIS requirements, and German specifics. This distinguishes it from sibling tools that deal with other regulatory topics like adverse events or device classification. While it lacks an explicit verb like 'retrieves' or 'provides', the intent is clear.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description implies that this tool is used when looking for clinical trial phase requirements under EU CTR, but it does not explicitly state when to use it over alternatives or provide exclusions. It offers context (EU CTR, CTIS, German specifics) but no direct guidance on tool selection.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.